3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Completed
3
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Endocrine
3
NET
1
Lymphoid
1
Conditions
Neuroendocrine Tumors
4
Carcinoma, Neuroendocrine
3
Neoplasms
2
Carcinoma, Merkel Cell
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Melanoma
1
Lymphoma, Follicular
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
Cisplatin
12
Everolimus
10
Nivolumab
8
Etoposide
8
Temozolomide
6
Carboplatin
6
atezolizumab
5
Irinotecan
5
Ipilimumab
5
Fluorouracil
5
Bevacizumab
5
pembrolizumab
4
lutetium Lu 177 dotatate
4
Capecitabine
4
avelumab
3
Paclitaxel
3
IFL protocol
3
surufatinib
2
sintilimab
2
gallium Ga 68 dotatate
2
dostarlimab
2
cabozantinib
2
belinostat
2
azaspirane
2
Topotecan
2
Radiosurgery
2
Positron Emission Tomography Computed Tomography
2
PE regimen
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Magnetic Resonance Imaging
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
avelumab
×
Endocrine
×
Clear all
NCT03352934
2022-02-25
AveNEC
Johannes Gutenberg University Mainz
Phase 2
Completed
60 enrolled
NCT03278405
2020-03-18
NET-001
Sunnybrook Health Sciences Centre
Phase 1/2
Completed
10 enrolled
NCT03147404
2019-12-30
MS100070-0177
Samsung Medical Center
Phase 2
Completed
14 enrolled